Established amyloid-β pathology is unaffected by chronic treatment with the selective serotonin reuptake inhibitor paroxetine

INTRODUCTION: Treatment with selective serotonin reuptake inhibitors has been suggested to mitigate amyloid-β (Aβ) pathology in Alzheimer's disease, in addition to an antidepressant mechanism of action. METHODS: We investigated whether chronic treatment with paroxetine, a selective serotonin re...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Alzheimers Dement (N Y)
Hlavní autoři: Severino, Maurizio, Sivasaravanaparan, Mithula, Olesen, Louise Ø., von Linstow, Christian U., Metaxas, Athanasios, Bouzinova, Elena V., Khan, Asif Manzoor, Lambertsen, Kate L., Babcock, Alicia A., Gramsbergen, Jan Bert, Wiborg, Ove, Finsen, Bente
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2018
Témata:
Featured Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6021554/
https://ncbi.nlm.nih.gov/pubmed/29955664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trci.2018.04.005
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky